Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 19,300 shares of the company’s stock in a transaction that occurred on Friday, January 26th. The stock was sold at an average price of $35.26, for a total transaction of $680,518.00. Following the sale, the chief executive officer now directly owns 743,675 shares in the company, valued at $26,221,980.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) remained flat at $$37.25 during trading hours on Monday. 1,209,742 shares of the company traded hands, compared to its average volume of 1,429,886. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $39.65. The company has a market capitalization of $1,400.45, a PE ratio of -10.73 and a beta of 1.27.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). analysts expect that Atara Biotherapeutics Inc will post -4 earnings per share for the current year.
Several equities research analysts recently weighed in on the stock. Cowen assumed coverage on shares of Atara Biotherapeutics in a research note on Friday. They set an “outperform” rating on the stock. BidaskClub raised shares of Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Canaccord Genuity reissued a “positive” rating and issued a $70.00 price objective (up from $47.00) on shares of Atara Biotherapeutics in a research report on Friday, January 19th. Citigroup raised shares of Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price objective on the stock in a research report on Wednesday, January 3rd. Finally, ValuEngine raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Four equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Atara Biotherapeutics currently has a consensus rating of “Buy” and an average target price of $30.60.
COPYRIGHT VIOLATION WARNING: “Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 19,300 Shares” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/29/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-19300-shares.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.